Extended pelvic lymph node dissection prolongs biochemical recurrence-free and metastasis-free survivals in localized prostate cancer.

A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer. Background: The therapeutic benefit of pelvic lymph node dissection (PLND) ...

The role of pelvic lymph node dissection (PLND) in patients with localized prostate cancer remains controversial. Although guidelines are increasingly recommending extended PLND alongside radical ...

A study of men with prostate cancer found no association between extent of lymph node dissection during radical prostatectomy and survival outcomes. New findings suggest that extensive lymph node ...

According to a new analysis, PLND does not impact recurrence-free survival but may reduce metastatic spread in intermediate- and high-risk prostate cancer. The benefit of PLND is most evident in ...

Extended dissection did not improve recurrence-free or overall survival, but it may have a bladder cancer-specific survival benefit possibly because it removes micrometastases. Extended lymph node ...

Dabrafenib and trametinib vs anti-PD(L)1 for the adjuvant treatment of locally advanced BRAF-mutant melanoma: A systematic review and meta-analysis. LN: lymph node. Zone I: inferior zone; Zone II: ...

N1 Single lymph node metastasis, 2 cm or less in greatest dimension N1 Single regional lymph node metastasis in the true pelvis (hypogastric, obturator, external iliac or presacral lymph node) N2 ...

Background: As the use of immune checkpoint inhibitors in postoperative adjuvant chemotherapy for patients with programmed death-ligand 1 (PD-L1)-expressing lung cancer has been increasing, it is ...